Are old, white men favored?

Despite consistent recommendations and growing clinical evidence, uptake of SGLT2i and GLP1 RA therapies in people with type 2 diabetes and cardiorenal comorbidities has been slow. There is also relatively little research on ethnic differences in those starting second-line therapy. This is an omission, as ethnic minority groups have higher rates of morbidity and mortality associated with type 2 diabetes.